Status: Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

The purpose of the study is to evaluate the experimental medication WD-890 compared to placebo in participants with moderate-to-severe plaque psoriasis.

Participants needed: 375

Trial details

Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Zhejiang Wenda Pharma Technology LTD.Updated: Jun 29, 2026Locations: 1

Eligibility criteria

Male or female participant aged 18 to 75 years(inclusive)at the time of informed... [+2]

Participant has a nonplaque form of psoriasis (for example, erythrodermic, gutta... [+2]

Status: Recruiting

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

Th purpose of the study is to evaluate the dose response of WD-890 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.

Participants needed: 140

Trial details

Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: Zhejiang Wenda Pharma Technology LTD.Updated: Apr 11, 2025Locations: 1

Eligibility criteria

Male or female participant aged 18 to 70 years(inclusive)at the time of informed... [+2]

Participant has a nonplaque form of psoriasis (for example, erythrodermic, gutta... [+3]

Status: Not yet recruiting

A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

This is a phase I, randomised, double-blind, placebo-controlled, 3-part study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of WD-910 in in Healthy Participants Detailed

Participants needed: 68

Trial details

Phase: Phase 1Age: 18-55Biological sex: AllType: InterventionalSponsor: Zhejiang Wenda Pharma Technology LTD.Updated: Apr 2, 2025Locations: 1

Eligibility criteria

Aged 18 to 55 years (inclusive) at the time of informed consent. [+1]

Any major surgery within 12 weeks prior to Day 1, or any planned surgery during... [+1]

Status: Recruiting

A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer

This is a multicenter, open-label, single-arm, phase II study to evaluate the efficacy, safety, and pharmacokinetics of NHWD-870 HCl in adults and adolescents with advanced NUT cancer.

Participants needed: 48

Trial details

Phase: Phase 2Age: 12-75Biological sex: AllType: InterventionalSponsor: Zhejiang Wenda Pharma Technology LTD.Updated: Jan 24, 2025Locations: 1

Eligibility criteria

A written informed consent signed; [+9]

Prior treatment with a BET inhibitor; [+4]

Clinical trials

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe Plaque Psoriasis

A Study of WD-890 in Participants With Moderate-to-Severe Plaque Psoriasis

A Phase I Randomised, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-910 in Healthy Participants

A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer